urea has been researched along with pimavanserin in 128 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (7.03) | 29.6817 |
| 2010's | 77 (60.16) | 24.3611 |
| 2020's | 42 (32.81) | 2.80 |
| Authors | Studies |
|---|---|
| Andersson, CM; Brann, MR; Burstein, ES; Davis, RE; Del Tredici, AL; Gardell, LR; Geyer, MA; Harvey, SC; Lameh, J; Makhay, M; Ott, TR; Piu, F; Powell, SB; Schiffer, HH; Schlienger, N; Son, TY; Thygesen, MB; Tolf, BR; Uldam, AK; Vanover, KE; Veinbergs, I; Weiner, DM | 1 |
| Roberts, C | 1 |
| Davis, RE; Mant, TG; Robbins-Weilert, D; van Kammen, DP; Vanover, KE; Weiner, DM; Wilbraham, DG | 2 |
| Anderson, GT; Barido, R; Bonhaus, DW; Brann, MR; Brunmark, P; Davis, RE; Dyssegaard, A; Gardell, LR; Hacksell, U; Johnson, RW; Pounds, L; Tabatabaei, A; Vanover, KE; Veinbergs, I | 1 |
| Brann, MR; Davis, RE; Farde, L; Hacksell, U; Halldin, C; Jovanovic, H; Karlsson, P; Mansson, M; Nordstrom, AL; Vanover, KE; Weiner, DM | 1 |
| Poyurovsky, M; Weizman, A; Weizman, R | 1 |
| Betz, AJ; Bibbiani, F; Chase, TN; Davis, RE; Kielaite, A; Salamone, JD; Vanover, KE; Weber, SM; Weiner, DM | 1 |
| Abbas, A; Roth, BL | 1 |
| Horiguchi, M; Huang, M; Li, Z; Meltzer, HY; Neill, JC; Shahid, M; Snigdha, S | 1 |
| Bahr, D; Friedman, JH; Johnson, A; Meltzer, HY; Mills, R; Revell, S; Williams, H | 1 |
| Burn, DJ; Docherty, MJ | 1 |
| Ancoli-Israel, S; Davis, RE; van Kammen, DP; Vanover, KE; Weiner, DM | 1 |
| Arnt, J; Ebdrup, BH; Glenthøj, B; Rasmussen, H | 1 |
| Bonhaus, DW; McFarland, K; Price, DL | 2 |
| Adelekun, AE; Hannaway, KE; Horiguchi, M; Jayathilake, K; Meltzer, HY | 1 |
| Elkis, H; Hacksell, U; Meltzer, HY; Peters, P; van Kammen, DP; Vanover, K; Weiner, DM | 1 |
| Antonini, A; Koutsikos, K; Pilleri, M | 1 |
| Krishnamurthi, N; Lieberman, A | 1 |
| Hacksell, U; Hubbard, D; McFarland, K | 1 |
| Friedman, JH | 2 |
| Ballard, C; Chi-Burris, K; Corbett, A; Cummings, J; Dhall, R; Isaacson, S; Mills, R; Williams, H | 1 |
| Fox, SH | 1 |
| Meltzer, HY; Roth, BL | 1 |
| Burstein, ES; Hacksell, U; McFarland, K; Mills, RG; Williams, H | 1 |
| Borek, LL; Friedman, JH | 1 |
| Horiguchi, M; Meltzer, HY; Miyauchi, M; Oyamada, Y; Rajagopal, L | 1 |
| Andersen, VL; Dyssegaard, A; Hansen, HD; Herth, MM; Knudsen, GM; Kristensen, JL | 1 |
| Cummings, J; Zhong, K | 1 |
| Ballard, C; Burn, DJ; Coate, B; Corbett, A; Isaacson, S; Mills, R; Pahwa, R; Rascol, O; Williams, H | 1 |
| Anderson, KC; Cox, A; Hunter, NS | 1 |
| Stevens, J | 1 |
| Banks, ML | 1 |
| Howland, RH | 1 |
| Traynor, K | 1 |
| Markham, A | 1 |
| Stahl, SM | 2 |
| Chendo, I; Ferreira, JJ | 1 |
| Majlath, Z; Obal, I; Vecsei, L | 1 |
| Chitnis, S; Khemani, P; Patel, N; Samudra, N; Womack, KB | 1 |
| Blier, P; Drago, F; Nutt, D; Stahl, S; Wilson, S; Zohar, J | 1 |
| Hussar, DA | 1 |
| Bozymski, KM; Crouse, EL; Gatesman, TL; Lowe, DK; Pasternak, KM | 1 |
| Ensom, MHH; Johnson, EG; Johnson, HE; Wilby, KJ | 1 |
| Finn, LA; Hussar, DA | 1 |
| Andreason, P; Atrakchi, A; Avila, AM; Farchione, T; Mathis, MV; Muoio, BM; Temple, RJ | 1 |
| Cozac, VV | 1 |
| Alva, G; Arquette, S; Espay, AJ; Farnum, C; Hermanowicz, N; Kenney, J; Kremens, D; Lopes, M; Madrid, KC; Pagan, F; Patel, A; Tereso, G | 1 |
| Duffy, A; Farias, S; Malhado-Chang, N; O'Connor, K; Olichney, J; Shahlaie, K; Sperry, L; Wheelock, V; Yuan, M; Zhang, L | 1 |
| Atchison, C; Fredericks, D; Norton, JC; Pill, MW; Schoenhaus, R | 1 |
| Aarsland, D; Ballard, C; Ffytche, D; Velayudhan, L | 1 |
| Kianirad, Y; Simuni, T | 1 |
| Sahli, ZT; Tarazi, FI | 1 |
| Chi-Burris, K; Citrome, L; Demos, G; Norton, JC | 1 |
| Chen, X; Chu, Y; Sun, X; Wang, S; Wang, Y; Wu, W; Zhang, J | 1 |
| Hermanowicz, N | 2 |
| Ondo, WG; Panchal, SC | 1 |
| Schneider, LS | 2 |
| Ballard, C; Banister, C; Coate, B; Cummings, J; Demos, G; Khan, Z; Owen, R; Stankovic, S; Youakim, JM | 1 |
| Webster, P | 1 |
| Ahmad, A; Bulica, B; Kaminski, P; Krstevska, S; LeWitt, P; Mahajan, A; Patel, N; Taylor, D | 1 |
| Schubmehl, S; Sussman, J | 2 |
| Butala, AA; Pontone, GM | 1 |
| Gandhi, R; Lessig, SL; Litvan, I; Moreno, GM; Nahab, FB; Wright, B | 1 |
| Jalal, B | 1 |
| Ballard, C; Cummings, J; Foff, E; Norton, J; Owen, R; Stankovic, S; Tariot, P; Youakim, J | 1 |
| Andersson, C; Ballard, C; Coate, B; Espay, AJ; Factor, SA; Fredericks, D; Friedman, JH; Guskey, MT; Lang, AE; Larsen, NJ; Norton, JC; Vizcarra, JA; Weintraub, D | 1 |
| Ballard, C; Coate, B; Stankovic, S; Youakim, JM | 1 |
| Citrome, L | 1 |
| Adler, CH; Alva, G; Black, KJ; Cooney, JW; Isaacson, S; Kremens, D; Menza, MA; Meyer, JM; Morrissette, DA; Nasrallah, H; Pahwa, R; Patkar, AA; Simuni, T; Stacy, M; Stahl, SM | 1 |
| Canal, C; de la Cruz, J | 1 |
| Fedora, R; Morton, R; Nasrallah, HA | 1 |
| Burstein, ES | 1 |
| Claassen, DO; Darby, RR; Farooque, A; Sellers, J | 1 |
| Boren, CB; Boren, RA | 1 |
| Lippmann, S; Mohanty, D; Naik, S; Sarai, S | 1 |
| Dirks, B; Fava, M; Freeman, MP; Liu, K; Papakostas, GI; Shelton, RC; Stankovic, S; Thase, ME; Trivedi, MH | 1 |
| Dahodwala, N; Horn, S; Richardson, H; Weintraub, D; Xie, SX | 1 |
| Andersen, ML; Dokkedal-Silva, V; Galduróz, JCF; Morelhão, PK; Tufik, S | 1 |
| Desai, R; Jain, S; Mansuri, Z; Patel, K; Zafar, MK | 1 |
| Hemine, K; Kernstein, A; Kozłowska-Tylingo, K; Skwierawska, A | 1 |
| Dirks, B; Fava, M; Freeman, MP; Jha, MK; Liu, K; Papakostas, GI; Shelton, RC; Stankovic, S; Thase, ME; Trivedi, MH | 4 |
| Bronstein, JM; Kyle, K | 2 |
| Jukić, MM | 1 |
| Cannavò, D; Caraci, F; Caruso, G; Drago, F; Leggio, GM; Salomone, S; Santagati, M | 1 |
| Abler, V; Azulay, JP; Ballard, CG; Demos, G; Fernandez, HH; Ferreira, JJ; Ilic, TV; Isaacson, S; Kreitzman, DL; Liu, IY; Norton, JC; Stankovic, S | 1 |
| Coate, B; Isaacson, SH; Norton, J; Stankovic, S | 1 |
| Abler, V; Ballard, CG; Coate, B; Foff, E; Stankovic, S | 1 |
| Abler, V; Aldred, JL; Alva, G; Cantillon, M; Coate, B; DeKarske, D; Jacobi, L; Norton, JC; Nunez, R | 1 |
| Cummings, JL; Devanand, DP; Stahl, SM | 1 |
| Alexander, GC; Mehta, HB; Moore, TJ | 1 |
| Cumming, P; Gründer, G | 1 |
| Jha, MK; Murrough, J; Ruberto, VL; Soogrim, V | 1 |
| Abler, V; Azulay, JP; Ballard, CG; Coate, B; Fernandez, HH; Ferreira, JJ; Ilic, TV; Isaacson, SH; Kreitzman, DL; Norton, JC; Stankovic, S | 1 |
| Aalapati, KK; Patnaik, RS; Singh, A | 1 |
| Atanasovski, D; Eriksson, E; Hagsäter, SM; Näslund, J; Pettersson, C; Pettersson, R | 1 |
| Ballard, C; Cummings, JL; Devanand, DP; Erten-Lyons, D; Foff, EP; McEvoy, B; Soto-Martin, ME; Stankovic, S; Sultzer, DL; Tariot, PN; Weintraub, D; Youakim, JM | 1 |
| Friedman, JI | 1 |
| Fan, RC; Gao, XQ; Ji, LZ; Jia, YP; Li, HL; Li, P; Liu, XN; Liu, ZZ; Tang, B; Wang, YQ; Yang, MQ; Zhang, QK; Zhou, YQ | 1 |
| Ali, F | 1 |
| Alexander, GC; An, H; Hwang, YJ; Mehta, HB; Moore, TJ | 1 |
| Howard, R; Liu, KY | 1 |
| Li, X; Tian, X | 1 |
| Abbs, B; Arango, C; Bugarski-Kirola, D; Fava, M; Liu, IY; Nasrallah, H; Stankovic, S | 1 |
| Burstein, ES; Elzokaky, A; Meltzer, HY; Rajagopal, L; Ryan, C | 1 |
| Dong, Z; He, L; Jiang, Y; Liu, K; Lu, X; Wang, Z; Wei, Y; Wu, W; Wu, X; Yu, Y; Yuan, Q; Zhao, J; Zhao, L; Zhou, H | 1 |
| Doshi, D; Subbiah, P; Turner, ME | 1 |
| Alexander, GC; Hwang, YJ; Mehta, HB; Moore, TJ | 1 |
| Ballard, C; Cummings, JL; Devanand, DP; Sultzer, DL; Tariot, PN | 1 |
| Adegbenle, YH; Bokser, AD; Norton, JC; Stoisavljevic, V | 1 |
| Crump, CJ; El-Mallakh, RS; Elsayed, OH; Litteral, CA | 1 |
| Akhtar, S; Feng, Y; Graham, DJ; Kelman, JA; Leishear, K; Liao, J; Lyu, H; Ma, Y; MaCurdy, TE; Mosholder, AD; Nelson, LM; Podskalny, GD; Wei, Y; Wernecke, M | 1 |
| Colijn, MA | 1 |
| Alakkas, A; Liu, L; Longardner, K; Nahab, FB; Wright, BA; Xu, R; You, H | 1 |
| Albujuq, NR; Alsehli, M; Althumayri, K; Diez-Alarcia, R; Meana, JJ; Muneta-Arrate, I; Naqvi, A | 1 |
| Akın, M; Kurhan, F | 1 |
33 review(s) available for urea and pimavanserin
| Article | Year |
|---|---|
ACP-103, a 5-HT2A receptor inverse agonist.
Topics: Animals; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Contraindications; Humans; Piperidines; Receptor, Serotonin, 5-HT2A; Serotonin Receptor Agonists; Structure-Activity Relationship; Urea | 2006 |
Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders.
Topics: Clinical Trials as Topic; Humans; Molecular Structure; Parkinson Disease; Piperidines; Schizophrenia; Serotonin 5-HT2 Receptor Agonists; Treatment Outcome; Urea | 2008 |
Parkinson's disease dementia.
Topics: Cholinesterase Inhibitors; Clinical Trials as Topic; Dementia; Diagnosis, Differential; Humans; Parkinson Disease; Piperidines; Urea | 2010 |
Serotonin 2A receptor antagonists for treatment of schizophrenia.
Topics: Antipsychotic Agents; Brain; Fluorobenzenes; Humans; Phenols; Piperidines; Positron-Emission Tomography; Receptor, Serotonin, 5-HT2A; Schizophrenia; Serotonin 5-HT2 Receptor Antagonists; Urea | 2011 |
Pimavanserin for the treatment of Parkinson's disease psychosis.
Topics: Animals; Antiparkinson Agents; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Serotonin 5-HT2 Receptor Agonists; Treatment Outcome; Urea | 2013 |
Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs.
Topics: Benzazepines; Diabetes Mellitus, Type 2; Heart Valve Diseases; Humans; Molecular Structure; Obesity; Parkinson Disease; Piperidines; Receptors, Serotonin; Schizophrenia; Serotonin; Serotonin 5-HT2 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Urea | 2013 |
On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis.
Topics: Drug Discovery; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Urea | 2014 |
Treating psychosis in movement disorder patients: a review.
Topics: Animals; Antipsychotic Agents; Clozapine; Humans; Movement Disorders; Piperidines; Psychotic Disorders; Treatment Outcome; Urea | 2014 |
Trial design innovations: Clinical trials for treatment of neuropsychiatric symptoms in Alzheimer's Disease.
Topics: Alzheimer Disease; Apathy; Citalopram; Clinical Trials as Topic; Cognition Disorders; Humans; Mental Disorders; Piperidines; Research Design; Therapies, Investigational; Treatment Outcome; Urea | 2015 |
Pimavanserin.
Topics: Animals; Clinical Trials as Topic; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Serotonin 5-HT2 Receptor Agonists; Urea | 2015 |
Pimavanserin: First Global Approval.
Topics: Antipsychotic Agents; Delusions; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Hallucinations; Humans; Molecular Structure; Parkinson Disease; Piperidines; Randomized Controlled Trials as Topic; Serotonin 5-HT2 Receptor Agonists; Treatment Outcome; Urea | 2016 |
Pimavanserin for the treatment of Parkinson's disease psychosis.
Topics: Antipsychotic Agents; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Schizophrenia; Serotonin 5-HT2 Receptor Agonists; Urea | 2016 |
Psychosis in Parkinson Disease: A Review of Etiology, Phenomenology, and Management.
Topics: Antipsychotic Agents; Cholinesterase Inhibitors; Clozapine; Humans; Molecular Targeted Therapy; Neurotransmitter Agents; Parkinson Disease; Piperidines; Psychotic Disorders; Quetiapine Fumarate; Urea | 2016 |
Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis.
Topics: Antiparkinson Agents; Antipsychotic Agents; Delusions; Hallucinations; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Urea | 2017 |
Evidence-Based Review of Pharmacotherapy Used for Parkinson's Disease Psychosis.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Evidence-Based Medicine; Humans; Olanzapine; Parkinson Disease; Piperazines; Piperidines; Practice Guidelines as Topic; Psychotic Disorders; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Thiazoles; Urea | 2017 |
The US Food and Drug Administration's Perspective on the New Antipsychotic Pimavanserin.
Topics: Antipsychotic Agents; Delusions; Hallucinations; Humans; Parkinson Disease; Piperidines; United States; United States Food and Drug Administration; Urea | 2017 |
The Emerging Role of Pimavanserin in the Management of Parkinson's Disease Psychosis.
Topics: Animals; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Quality of Life; Urea | 2017 |
Parkinson's disease and Parkinson's disease psychosis: a perspective on the challenges, treatments, and economic burden.
Topics: Antipsychotic Agents; Cost of Illness; Health Care Costs; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Urea | 2017 |
New Therapeutic Strategies for Lewy Body Dementias.
Topics: alpha-Synuclein; Cholinesterase Inhibitors; Disease Management; Genetic Therapy; Humans; Lewy Body Disease; Parkinson Disease; Piperidines; Stem Cell Transplantation; Urea | 2017 |
Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis.
Topics: Antipsychotic Agents; Delusions; Drug Inverse Agonism; Hallucinations; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Serotonin 5-HT2 Receptor Agonists; Urea | 2017 |
Pimavanserin: novel pharmacotherapy for Parkinson's disease psychosis.
Topics: Animals; Antipsychotic Agents; Delusions; Hallucinations; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Urea | 2018 |
Pimavanserin for the treatment of Parkinson's disease psychosis: number needed to treat, number needed to harm, and likelihood to be helped or harmed.
Topics: Clinical Trials as Topic; Humans; Numbers Needed To Treat; Parkinson Disease; Piperidines; Psychotic Disorders; Serotonin 5-HT2 Receptor Antagonists; Urea | 2018 |
Delusional misidentification in Parkinson's disease: report of two cases and a review.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delusions; Female; Humans; Male; Parkinson Disease; Piperidines; Urea | 2018 |
Treating Hallucinations and Delusions Associated With Parkinson's Disease Psychosis.
Topics: Antipsychotic Agents; Delusions; Hallucinations; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Serotonin 5-HT2 Receptor Antagonists; Urea | 2018 |
Pharmacological interventions for psychosis in Parkinson's disease patients.
Topics: Antipsychotic Agents; Clozapine; Dopamine; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Quetiapine Fumarate; Urea | 2018 |
The neuropharmacology of sleep paralysis hallucinations: serotonin 2A activation and a novel therapeutic drug.
Topics: Animals; Dopamine; Hallucinations; Hallucinogens; Humans; Lysergic Acid Diethylamide; Neuropharmacology; Piperidines; Psilocybin; Receptor, Serotonin, 5-HT2A; Serotonin; Serotonin 5-HT2 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Sleep; Sleep Paralysis; Urea | 2018 |
Pimavanserin: Potential Treatment For Dementia-Related Psychosis.
Topics: Alzheimer Disease; Clinical Trials as Topic; Dementia; Humans; Mental Status and Dementia Tests; Parkinson Disease; Piperidines; Psychotic Disorders; Serotonin 5-HT2 Receptor Antagonists; Severity of Illness Index; Treatment Outcome; Urea | 2018 |
Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus.
Topics: Antiparkinson Agents; Antipsychotic Agents; Consensus; Drug Substitution; Humans; Off-Label Use; Parkinson Disease; Piperidines; Practice Guidelines as Topic; Psychotic Disorders; Serotonin 5-HT2 Receptor Antagonists; Urea | 2018 |
Treatment of psychosis in Parkinson's disease and dementia with Lewy Bodies: A review.
Topics: Antipsychotic Agents; Humans; Lewy Body Disease; Parkinson Disease; Piperidines; Psychotic Disorders; Urea | 2020 |
New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer's disease: focus on brexpiprazole and pimavanserin.
Topics: Alzheimer Disease; Antipsychotic Agents; Anxiety; Humans; Piperidines; Psychotic Disorders; Quinolones; Thiophenes; Urea | 2020 |
Dementia-related psychosis and the potential role for pimavanserin.
Topics: Dementia; Hallucinations; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Urea | 2022 |
Spotlight on Pimavanserin Tartrate and Its Therapeutic Potential in the Treatment of Major Depressive Disorder: The Evidence to Date.
Topics: Antipsychotic Agents; Depressive Disorder, Major; Humans; Piperidines; Receptors, Serotonin; Urea | 2021 |
A New Hope in Alzheimer's Disease Psychosis: Pimavanserin.
Topics: Alzheimer Disease; Antipsychotic Agents; Humans; Parkinson Disease; Psychotic Disorders; United States; Urea | 2023 |
21 trial(s) available for urea and pimavanserin
| Article | Year |
|---|---|
Pharmacokinetics, tolerability, and safety of ACP-103 following single or multiple oral dose administration in healthy volunteers.
Topics: Adolescent; Adult; Area Under Curve; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Half-Life; Humans; Male; Middle Aged; Piperidines; Serotonin 5-HT2 Receptor Agonists; Urea | 2007 |
The effects of food on the pharmacokinetics of a formulated ACP-103 tablet in healthy volunteers.
Topics: Adolescent; Adult; Antipsychotic Agents; Biological Availability; Cross-Over Studies; Fasting; Food-Drug Interactions; Half-Life; Humans; Male; Middle Aged; Piperidines; Psychotic Disorders; Serotonin 5-HT2 Receptor Agonists; Tablets; Therapeutic Equivalency; Urea | 2007 |
PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Binding, Competitive; Brain; Carbon Radioisotopes; Dose-Response Relationship, Drug; Drug Inverse Agonism; Humans; Male; Piperidines; Positron-Emission Tomography; Radiopharmaceuticals; Receptor, Serotonin, 5-HT2A; Spiperone; Urea | 2008 |
Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.
Topics: Aged; Analysis of Variance; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Motor Activity; Parkinson Disease; Piperidines; Psychiatric Status Rating Scales; Psychotic Disorders; Serotonin 5-HT2 Receptor Agonists; Serotonin Receptor Agonists; Severity of Illness Index; Urea | 2010 |
Pimavanserin tartrate, a 5-HT(2A) receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteers.
Topics: Adult; Aged; Double-Blind Method; Female; Human Experimentation; Humans; Male; Middle Aged; Patient Compliance; Piperidines; Placebo Effect; Polysomnography; Serotonin 5-HT2 Receptor Antagonists; Sleep; Urea | 2011 |
Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Female; Follow-Up Studies; Haloperidol; Humans; Male; Middle Aged; Piperidines; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Time Factors; Urea; Young Adult | 2012 |
Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Antipsychotic Agents; Double-Blind Method; Female; Humans; Male; Parkinson Disease; Piperidines; Psychotic Disorders; Serotonin 5-HT2 Receptor Agonists; Treatment Outcome; Urea | 2014 |
Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis.
Topics: Accidental Falls; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Antipsychotic Agents; Drug Therapy, Combination; Edema; Female; Humans; Hypotension, Orthostatic; Infections; Male; Middle Aged; Parkinson Disease; Piperidines; Psychotic Disorders; Stroke; Thromboembolism; Urea | 2015 |
Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Double-Blind Method; Female; Humans; Male; Nursing Homes; Piperidines; Psychiatric Status Rating Scales; Psychotic Disorders; Treatment Outcome; Urea | 2018 |
Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Female; Humans; Male; Mental Status Schedule; Middle Aged; Nootropic Agents; Parkinson Disease; Piperidines; Psychotic Disorders; Treatment Outcome; Urea | 2018 |
Pimavanserin in Alzheimer's Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Double-Blind Method; Female; Humans; Male; Middle Aged; Nursing Homes; Piperidines; Psychotic Disorders; Serotonin 5-HT2 Receptor Antagonists; Treatment Outcome; Urea | 2019 |
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin in Patients With Major Depressive Disorder and an Inadequate Response to Therapy (CLARITY).
Topics: Adult; Aged; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperidines; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Urea; Young Adult | 2019 |
Blinded SAPS-PD Assessment After 10 Weeks of Pimavanserin Treatment for Parkinson's Disease Psychosis.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Piperidines; Psychotic Disorders; Serotonin 5-HT2 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Urea | 2020 |
Evaluation of the efficacy of pimavanserin in the treatment of agitation and aggression in patients with Alzheimer's disease psychosis: A post hoc analysis.
Topics: Aggression; Alzheimer Disease; Double-Blind Method; Humans; Piperidines; Psychomotor Agitation; Psychotic Disorders; Treatment Outcome; Urea | 2020 |
An Open-Label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults with Parkinson's Disease and Depression.
Topics: Aged; Depression; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Piperidines; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT2 Receptor Antagonists; Serotonin and Noradrenaline Reuptake Inhibitors; Urea | 2020 |
Effect of pimavanserin on anxious depression in patients with major depression and an inadequate response to previous therapy: secondary analysis of the clarity study.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Anxiety; Depression; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperidines; Urea | 2020 |
Effect of adjunctive pimavanserin on suicidal ideation in patients with major depression: Analysis of the CLARITY study.
Topics: Adult; Depression; Depressive Disorder, Major; Double-Blind Method; Humans; Piperidines; Suicidal Ideation; Urea | 2020 |
Effect of Adjunctive Pimavanserin on Sleep/Wakefulness in Patients With Major Depressive Disorder: Secondary Analysis From CLARITY.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Linear Models; Male; Middle Aged; Piperidines; Serotonin 5-HT2 Receptor Antagonists; Sleep Wake Disorders; Treatment Outcome; Urea; Young Adult | 2020 |
Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patients.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Double-Blind Method; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Piperidines; Psychotic Disorders; Urea | 2021 |
Trial of Pimavanserin in Dementia-Related Psychosis.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Dementia; Double-Blind Method; Female; Hallucinations; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Parkinson Disease; Piperidines; Proportional Hazards Models; Psychotic Disorders; Recurrence; Urea | 2021 |
Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe.
Topics: Adolescent; Adult; Double-Blind Method; Europe; Female; Humans; Male; Middle Aged; North America; Outcome Assessment, Health Care; Piperidines; Schizophrenia; Serotonin 5-HT2 Receptor Antagonists; Urea; Young Adult | 2022 |
74 other study(ies) available for urea and pimavanserin
| Article | Year |
|---|---|
Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist.
Topics: Animals; Behavior, Animal; Biological Availability; Cloning, Molecular; Humans; Male; Mice; NIH 3T3 Cells; Piperidines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Urea | 2006 |
ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.
Topics: Amphetamine; Amphetamines; Animals; Antipsychotic Agents; Behavior, Animal; Brain Chemistry; Catalepsy; Dizocilpine Maleate; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Drug Synergism; Haloperidol; Head Movements; Male; Mice; Mice, Inbred Strains; Motor Activity; Piperidines; Prolactin; Rats; Rats, Sprague-Dawley; Risperidone; Serotonin 5-HT2 Receptor Agonists; Serotonin Receptor Agonists; Urea | 2007 |
Aripiprazole's receptor pharmacology and extrapyramidal side effects.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Humans; Piperazines; Piperidines; Positron-Emission Tomography; Psychomotor Agitation; Quinolones; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Urea | 2008 |
A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model.
Topics: Animals; Data Interpretation, Statistical; Dopamine Agents; Dyskinesia, Drug-Induced; Jaw; Levodopa; Macaca fascicularis; Male; MPTP Poisoning; Piperidines; Rats; Rats, Sprague-Dawley; Serotonin 5-HT2 Receptor Agonists; Serotonin Receptor Agonists; Tremor; Urea | 2008 |
Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist.
Topics: Animals; Antipsychotic Agents; Dopamine D2 Receptor Antagonists; Drug Interactions; Drug Inverse Agonism; Female; Fluorobenzenes; Phencyclidine; Piperidines; Random Allocation; Rats; Rats, Long-Evans; Recognition, Psychology; Serotonin 5-HT2 Receptor Antagonists; Urea | 2010 |
Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease.
Topics: Amphetamine; Amphetamines; Animals; Antipsychotic Agents; Behavior, Animal; Central Nervous System Stimulants; Disease Models, Animal; Dyskinesias; Fenfluramine; Fluorobenzenes; Hyperkinesis; Male; Motor Activity; Oxidopamine; Parkinson Disease; Piperidines; Psychotic Disorders; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Sensory Gating; Serotonin 5-HT2 Receptor Antagonists; Serotonin Agents; Serotonin Receptor Agonists; Substantia Nigra; Tyrosine 3-Monooxygenase; Urea | 2011 |
Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist.
Topics: Animals; Cognition Disorders; Disease Models, Animal; Dopamine D2 Receptor Antagonists; Female; Haloperidol; Isoindoles; Lurasidone Hydrochloride; Phencyclidine; Piperazines; Piperidines; Pyridines; Pyrimidines; Rats; Rats, Long-Evans; Receptors, N-Methyl-D-Aspartate; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT1 Receptor Antagonists; Serotonin 5-HT2 Receptor Agonists; Thiazoles; Urea | 2012 |
Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer's disease.
Topics: Alzheimer Disease; Amphetamine; Amphetamines; Animals; Antipsychotic Agents; Behavior, Animal; Disease Models, Animal; Drug Inverse Agonism; Male; Mice; Piperidines; Psychotic Disorders; Serotonin 5-HT2 Receptor Antagonists; Urea | 2012 |
Is there room for new non-dopaminergic treatments in Parkinson's disease?
Topics: Antiparkinson Agents; Droxidopa; Humans; Parkinson Disease; Piperidines; Urea | 2013 |
Is there room for non-dopaminergic treatment in Parkinson disease?
Topics: Antiparkinson Agents; Droxidopa; Humans; Parkinson Disease; Piperidines; Treatment Outcome; Urea | 2013 |
Behavioral effects of clozapine, pimavanserin, and quetiapine in rodent models of Parkinson's disease and Parkinson's disease psychosis: evaluation of therapeutic ratios.
Topics: Amphetamine; Animals; Antiparkinson Agents; Antipsychotic Agents; Apomorphine; Clozapine; Dopamine; Dose-Response Relationship, Drug; Male; Parkinsonian Disorders; Piperidines; Psychotic Disorders; Quetiapine Fumarate; Rats; Rats, Sprague-Dawley; Urea | 2013 |
Pimavanserin as treatment for Parkinson's disease psychosis.
Topics: Antiparkinson Agents; Antipsychotic Agents; Female; Humans; Male; Parkinson Disease; Piperidines; Psychotic Disorders; Serotonin 5-HT2 Receptor Agonists; Urea | 2014 |
Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dopamine D2 Receptor Antagonists; Haloperidol; Isoindoles; Memory Disorders; Phencyclidine; Piperazines; Piperidines; Pyrimidines; Random Allocation; Rats, Long-Evans; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Recognition, Psychology; Schizophrenia; Schizophrenic Psychology; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT2 Receptor Agonists; Urea | 2015 |
(11)C-labeling and preliminary evaluation of pimavanserin as a 5-HT2A receptor PET-radioligand.
Topics: Animals; Carbon Radioisotopes; Ligands; Methylation; Piperidines; Positron-Emission Tomography; Radiopharmaceuticals; Receptor, Serotonin, 5-HT2A; Serotonin 5-HT2 Receptor Agonists; Swine; Urea | 2015 |
Market watch: Upcoming market catalysts in Q2 2016.
Topics: Adrenergic Uptake Inhibitors; Antiparkinson Agents; Drug Approval; Drug Discovery; Humans; Piperidines; Tetrabenazine; United States; United States Food and Drug Administration; Urea | 2016 |
Effects of 7-day repeated treatment with the 5-HT2A inverse agonist/antagonist pimavanserin on methamphetamine vs. food choice in male rhesus monkeys.
Topics: Animals; Choice Behavior; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Inverse Agonism; Feeding Behavior; Food; Macaca mulatta; Male; Methamphetamine; Piperidines; Reinforcement, Psychology; Self Administration; Serotonin 5-HT2 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Treatment Outcome; Urea | 2016 |
Pimavanserin: An Inverse Agonist Antipsychotic Drug.
Topics: Female; Humans; Male; Parkinson Disease; Piperidines; Psychotic Disorders; Serotonin 5-HT2 Receptor Agonists; Urea | 2016 |
Pimavanserin (Nuplazid) for Parkinson's disease psychosis.
Topics: Antiparkinson Agents; Antipsychotic Agents; Drug Administration Schedule; Drug Costs; Drug Interactions; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Treatment Outcome; Urea | 2016 |
Pimavanserin approved for Parkinson's-related hallucinations, delusions.
Topics: Antiparkinson Agents; Delusions; Drug Approval; Drug Labeling; Hallucinations; Humans; Parkinson Disease; Piperidines; Urea | 2016 |
Mechanism of action of pimavanserin in Parkinson's disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors.
Topics: Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2C; Serotonin 5-HT2 Receptor Agonists; Urea | 2016 |
Parkinson's disease psychosis as a serotonin-dopamine imbalance syndrome.
Topics: Antiparkinson Agents; Antipsychotic Agents; Brain; Dopamine; Humans; Levodopa; Lewy Bodies; Parkinson Disease; Piperidines; Psychotic Disorders; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Serotonin; Urea | 2016 |
Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin.
Topics: Animals; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Receptor, Serotonin, 5-HT2A; Serotonin 5-HT2 Receptor Agonists; Urea | 2017 |
Inverse agonists - What do they mean for psychiatry?
Topics: Animals; Humans; Mental Disorders; Piperidines; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT1 Receptor Antagonists; Urea | 2017 |
New Drugs 2017, part 1.
Topics: Antibodies, Monoclonal, Humanized; Drug Approval; Drug Therapy; Humans; Insulin, Long-Acting; Piperazines; Piperidines; Polymers; Pyrrolidinones; United States; United States Food and Drug Administration; Urea | 2017 |
2017 New Drug Update.
Topics: Anti-Inflammatory Agents; Antipsychotic Agents; Drugs, Investigational; Dry Eye Syndromes; Gout Suppressants; Humans; Hypoglycemic Agents; Insulin, Long-Acting; Peptides; Phenylalanine; Piperidines; Sulfones; Thioglycolates; Triazoles; Urea | 2017 |
[Modern approaches to treatment of psychosis in Parkinson's disease].
Topics: Antiparkinson Agents; Antipsychotic Agents; Clozapine; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Quality of Life; Quetiapine Fumarate; Urea | 2016 |
Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Olanzapine; Outcome and Process Assessment, Health Care; Parkinson Disease; Piperidines; Psychological Techniques; Psychotic Disorders; Quality of Life; Retrospective Studies; Urea | 2017 |
Investigation of metabolic profile of pimavanserin in rats by ultrahigh-performance liquid chromatography combined with Fourier transform ion cyclotron resonance mass spectrometry.
Topics: Administration, Oral; Animals; Bile; Chromatography, High Pressure Liquid; Feces; Fourier Analysis; Male; Mass Spectrometry; Piperidines; Rats, Sprague-Dawley; Tissue Distribution; Urea | 2018 |
Pimavanserin for patients with Alzheimer's disease psychosis.
Topics: Alzheimer Disease; Double-Blind Method; Humans; Piperidines; Psychotic Disorders; Urea | 2018 |
Pimavanserin evaluated by the FDA.
Topics: Antipsychotic Agents; Delusions; Drug Evaluation; Hallucinations; Humans; Parkinson Disease; Piperidines; United States; United States Food and Drug Administration; Urea | 2018 |
Difficult choices in treating Parkinson's disease psychosis.
Topics: Antipsychotic Agents; Drug Approval; Humans; Off-Label Use; Parkinson Disease; Piperidines; Psychotic Disorders; United States; United States Food and Drug Administration; Urea | 2018 |
Pimavanserin use in a movement disorders clinic: a single-center experience.
Topics: Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Male; Middle Aged; Movement Disorders; Piperidines; Retrospective Studies; Serotonin 5-HT2 Receptor Agonists; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome; Urea | 2018 |
Perspective on Pimavanserin and the SAPS-PD: Novel Scale Development as a Means to FDA Approval.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Drug Approval; Humans; Outcome Assessment, Health Care; Parkinson Disease; Piperidines; Psychiatric Status Rating Scales; Psychotic Disorders; Urea | 2018 |
Absence of Evidence Versus Evidence of Absence-SAPS-PD.
Topics: Humans; Piperidines; Urea | 2018 |
FDA Approval of Pimavanserin: Response to Absence of Evidence Versus Evidence of Absence-Pimavanserin and the SAPS-PD.
Topics: Humans; Piperidines; Urea | 2018 |
Mortality in patients with Parkinson disease psychosis receiving pimavanserin and quetiapine.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Female; Humans; Male; Middle Aged; Parkinson Disease; Piperidines; Psychotic Disorders; Quetiapine Fumarate; Retrospective Studies; Survival Analysis; Treatment Outcome; Urea | 2018 |
Psychiatric commentary addressing the article titled "Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus".
Topics: Antipsychotic Agents; Consensus; Humans; Neurodegenerative Diseases; Off-Label Use; Parkinson Disease; Piperidines; Psychotic Disorders; Quality of Life; Urea | 2018 |
Neurological commentary addressing the article titled "Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus".
Topics: Antipsychotic Agents; Consensus; Humans; Off-Label Use; Parkinson Disease; Piperidines; Psychotic Disorders; Urea | 2018 |
Can pimavanserin help patients with Parkinson disease psychosis?
Topics: Antipsychotic Agents; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Serotonin 5-HT2 Receptor Antagonists; Urea | 2019 |
Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist.
Topics: Adult; Aged; Antipsychotic Agents; Clozapine; Delusions; Drug Resistance; Female; Hallucinations; Humans; Male; Middle Aged; Piperidines; Psychotic Disorders; Retrospective Studies; Schizophrenia; Serotonin 5-HT2 Receptor Antagonists; Urea; Young Adult | 2019 |
Should inverse agonists be defined by pharmacological mechanism or clinical effect?
Topics: Antiparkinson Agents; Antipsychotic Agents; Humans; Piperidines; Urea | 2019 |
Pimavanserin for Psychosis in Parkinson's Disease-Related Disorders: A Retrospective Chart Review.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Female; Humans; Male; Parkinson Disease; Piperidines; Psychotic Disorders; Retrospective Studies; Urea | 2019 |
Charles Bonnet Syndrome Treated With Pimavanserin.
Topics: Aged, 80 and over; Charles Bonnet Syndrome; Humans; Male; Piperidines; Serotonin 5-HT2 Receptor Antagonists; Urea | 2019 |
Pimavanserin for Parkinson Disease Psychosis.
Topics: Antiparkinson Agents; Antipsychotic Agents; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Urea | 2019 |
Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson's disease and dementia with Lewy bodies.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Cohort Studies; Female; Humans; Lewy Body Disease; Male; Middle Aged; Parkinson Disease; Piperidines; Psychotic Disorders; Quetiapine Fumarate; Retrospective Studies; Urea | 2019 |
The use of Pimavanserin in the treatment of Parkinson's disease: a consideration of its effects on sleep.
Topics: Cross-Sectional Studies; Genotype; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Sleep; Urea | 2020 |
Pimavanserin: A 2019 Clarification on the FDA Update.
Topics: Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Urea | 2019 |
Cyclodextrin polymers as efficient adsorbents for removing toxic non-biodegradable pimavanserin from pharmaceutical wastewaters.
Topics: Adsorption; beta-Cyclodextrins; Cellulose; Cyclodextrins; Industrial Waste; Pharmaceutical Preparations; Piperidines; Polymers; Urea; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical | 2020 |
Improvement of sexual functioning during treatment of MDD with adjunctive pimavanserin: A secondary analysis.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Longitudinal Studies; Male; Middle Aged; Norepinephrine; Piperidines; Selective Serotonin Reuptake Inhibitors; Serotonin; Sexual Dysfunction, Physiological; Treatment Outcome; Urea | 2020 |
Can G
Topics: Brain; GTP-Binding Protein alpha Subunits, Gq-G11; Humans; Piperidines; Psychotic Disorders; Receptor, Serotonin, 5-HT2A; Serotonin; Serotonin 5-HT2 Receptor Agonists; Urea | 2020 |
Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Female; Hallucinations; Humans; Male; Middle Aged; Parkinson Disease; Piperidines; Psychotic Disorders; Urea | 2020 |
Association of Pharmaceutical Industry Payments to Physicians With Prescription and Medicare Expenditures for Pimavanserin.
Topics: Aged; Cross-Sectional Studies; Drug Industry; Health Expenditures; Humans; Medicare Part D; Physicians; Piperidines; Practice Patterns, Physicians'; Prescription Drugs; Prescriptions; Retrospective Studies; United States; Urea | 2021 |
Treatment of Psychosis in Parkinson's disease and sudden death.
Topics: Antipsychotic Agents; Death, Sudden; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Urea | 2020 |
Serotonin and amyloid deposition: A link between depression and Alzheimer's disease?: An Editorial Highlight on "Pimavanserin, a 5HT
Topics: Alzheimer Disease; Animals; Brain; Depression; Disease Models, Animal; Mice; Mice, Transgenic; Pharmaceutical Preparations; Piperidines; Receptor, Serotonin, 5-HT2A; Serotonin; Serotonin 5-HT2 Receptor Agonists; Urea | 2021 |
A Fully Validated UHPLC-MS/MS Method for the Estimation of Pimavanserin in Human (K2EDTA) Plasma and its Application to a Clinical Pharmacokinetic Study.
Topics: Chromatography, High Pressure Liquid; Humans; Piperidines; Reproducibility of Results; Tandem Mass Spectrometry; Urea | 2022 |
A Complex Impact of Systemically Administered 5-HT2A Receptor Ligands on Conditioned Fear.
Topics: Animals; Behavior, Animal; Bridged Bicyclo Compounds; Conditioning, Classical; Fear; Fluorobenzenes; Ligands; Male; Methylamines; Piperidines; Psilocybin; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT2 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Urea | 2021 |
Pimavanserin in Dementia-Related Psychosis.
Topics: Dementia; Humans; Piperidines; Psychotic Disorders; Urea | 2021 |
Identification of pimavanserin tartrate as a potent Ca
Topics: Animals; Brain Neoplasms; Calcineurin; Calcineurin Inhibitors; Calcium Signaling; Calcium-Binding Proteins; Cell Line, Tumor; Cell Movement; Dose-Response Relationship, Drug; Female; Glioblastoma; HeLa Cells; Humans; Male; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; NFATC Transcription Factors; Piperidines; Urea; Xenograft Model Antitumor Assays | 2021 |
Pimavanserin: A Friend or Foe in Parkinson Disease Psychosis.
Topics: Aged; Hospitalization; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Urea | 2021 |
Risk of Hospitalization and Death Associated With Pimavanserin Use in Older Adults With Parkinson Disease.
Topics: Aged; Hospitalization; Humans; Medicare; Parkinson Disease; Piperidines; Psychotic Disorders; Retrospective Studies; United States; Urea | 2021 |
Pimavanserin and dementia-related psychosis: can HARMONY prevail?
Topics: Clinical Trials as Topic; Dementia; Humans; Piperidines; Psychotic Disorders; Urea | 2021 |
The protective effects of Pimavanserin against cerebral ischemia-induced brain injury.
Topics: Animals; Blood-Brain Barrier; Cell Line; Endothelial Cells; Infarction, Middle Cerebral Artery; Mice; Piperidines; Protective Agents; Tight Junctions; Urea | 2021 |
Pimavanserin augments the efficacy of atypical antipsychotic drugs in a mouse model of treatment-refractory negative symptoms of schizophrenia.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Male; Mice; Mice, Inbred C57BL; Piperidines; Schizophrenia, Treatment-Resistant; Urea | 2022 |
Nuplazid suppresses esophageal squamous cell carcinoma growth in vitro and in vivo by targeting PAK4.
Topics: Cell Line, Tumor; Cell Proliferation; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gene Expression Regulation, Neoplastic; Humans; p21-Activated Kinases; Piperidines; Urea | 2022 |
Reader Response: Risk of Hospitalization and Death Associated With Pimavanserin Use in Older Adults With Parkinson Disease.
Topics: Aged; Hospitalization; Humans; Parkinson Disease; Piperidines; Urea | 2022 |
Author Response: Risk of Hospitalization and Death Associated With Pimavanserin Use in Older Adults With Parkinson Disease.
Topics: Aged; Hospitalization; Humans; Parkinson Disease; Piperidines; Urea | 2022 |
Pimavanserin and dementia-related psychosis.
Topics: Dementia; Humans; Piperidines; Psychotic Disorders; Urea | 2022 |
In Vitro Stability and Recovery Studies of Pimavanserin in Water and in Different Vehicles Orally Administered.
Topics: Adult; Aged; Hallucinations; Humans; Piperidines; Urea; Water | 2022 |
Pimavanserin for bipolar disorder.
Topics: Bipolar Disorder; Humans; Piperidines; Psychotic Disorders; Urea | 2022 |
Mortality Among Parkinson's Disease Patients Treated With Pimavanserin or Atypical Antipsychotics: An Observational Study in Medicare Beneficiaries.
Topics: Aged; Antipsychotic Agents; Cohort Studies; Female; Humans; Male; Medicare; Parkinson Disease; Piperidines; Psychotic Disorders; Retrospective Studies; United States; Urea | 2022 |
The Therapeutic Potential of Pimavanserin in the Treatment of Hallucinogen Induced Psychosis and Persistent Perceptual Symptoms.
Topics: Hallucinogens; Humans; Piperidines; Psychotic Disorders; Urea | 2022 |
The Safety of Pimavanserin for Parkinson's Disease and Efforts to Reduce Antipsychotics for People With Dementia.
Topics: Antipsychotic Agents; Dementia; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Urea | 2022 |
Assessing the risks of treatment in Parkinson disease psychosis: An in-depth analysis.
Topics: Aged; Antipsychotic Agents; Dementia; Humans; Levodopa; Parkinson Disease; Prospective Studies; Psychotic Disorders; Quetiapine Fumarate; Retrospective Studies; Urea | 2023 |
Design, Synthesis, Molecular Docking, and Biological Evaluation of Novel Pimavanserin-Based Analogues as Potential Serotonin 5-HT
Topics: Antipsychotic Agents; Drug Inverse Agonism; Humans; Molecular Docking Simulation; Psychotic Disorders; Receptor, Serotonin, 5-HT2A; Serotonin; Serotonin 5-HT2 Receptor Agonists; Serotonin Receptor Agonists; Urea | 2023 |